Abstract
Keywords
ADR Reporting (25)Anlotinib (6)Anti-Tuberculin Therapy (7)Belimumab (21)Checkpoint Immune Inhibitors (20)Contrast Media (1)DTaP-IPV/Hib Pentavalent Vaccine (24)Docetaxel (17)EGFRIs (14)Empagliflozin (19)Fluvoxamine (22)Gefitinib (17)GLP-1 Receptor Antagonists (11,12,13)Hand Sanitizer (29)Heparin (Unfractionated) (18)Ibrutinib (26)Immune Checkpoint Inhibitors (3,28)Immune Globulin (IV) (2)Janus Kinase Inhibitors (8)Lithium (19)Lomitapide (9)Medications (4,23,30)Mesalazine (27)Proton Pump Inhibitors (31)Rituximab (21)SERDs (10)Tislelizumab (16)TNF-Inhibitors (21)TNF-α Inhibitors (15)Vaccines (5)
Get full access to this article
View all access options for this article.